Recruiting

HAART with Abacavir

Sponsor:

Clinical Alliance for Research & Education - Infectious Diseases, LLC.

Code:

NCT00426296

Conditions

HIV Infections

Lipodystrophy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

atazanavir (Reyataz)

ritonavir (Norvir)

Study Details

Brief summary:

SHARE: Simple HAART with Abacavir, Reyataz, and Epivir

Conditions

HIV Infections

Lipodystrophy

Study ID

NCT00426296

Start date

Aug, 2006

Status verified date

Oct, 2007

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen
  • Viral load <50 copies/ml

Exclusion Criteria:

  • Viral load >50 copies/ml
  • Having taken more than one antiretroviral regimen

Study Design

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Interventions

atazanavir (Reyataz)

ritonavir (Norvir)

Central Contacts and Locations

Central contacts

Richard A. Elion, MD

drrelion@aol.com

Locations

Whitman-Walker Clinic

Recruiting

Washington, District of Columbia, United States

Contacts

Richard Elion, MD

drrelion@aol.com

Principal Investigator:

Richard A Elion, MD

More Information

Sponsor

Clinical Alliance for Research & Education - Infectious Diseases, LLC.

Last update posted

Nov 1, 2007

Last verified

Oct, 2007

Keywords

  • HIV
  • Reyataz
  • atazanavir
  • Norvir
  • ritonavir
  • Boosted
  • Lipodystrophy
  • Treatment Experienced

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Clinical Alliance for Research & Education - Infectious Diseases, LLC. on 2007-11-01.